




## Annex to the Press Release

### Evolution diagnostic trade sales (in thousands EUR)



**HPV:** Human papillomaviruses are a group of over 100 types of viruses of which 30 are sexually transmissible. Specific high-risk HPVs are the major cause of cervical cancer, the second most common cancer in women.

**HLA:** Human leukocyte antigen: a set of proteins expressed on the surface of cells that allow the body to discriminate between self and non-self. Before transplantation, the process of tissue typing determines the presence and absence of these proteins to ensure that the organ donor and recipient are compatible.

**LiPA** or line probe assay is a DNA-based, multiparameter (ie, able to measure many items with one test) detection and identification technology that provides high value-added diagnostic information to physicians throughout therapy, enabling them to optimize the therapeutic regimen of patients.

**LIA**<sup>®</sup> or line immunoassay tests are advanced confirmatory tests allowing rapid and simultaneous detection and differentiation of multiple disease parameters, such as antibodies, in human serum or plasma samples.



**INNOGENETICS**<sup>®</sup>  
BIOTECHNOLOGY FOR HEALTHCARE

## Unaudited Consolidated Income Statement

All information in thousands EUR, except share amounts  
According to IFRS

	6 months ended		3 months ended	
	June 2008	June 2007	June 2008	June 2007
Product sales	27.552	25.482	14.283	13.227
Royalties	1.916	1.895	916	920
License fees	1.158	22	169	11
<b>Revenues</b>	<b>30.626</b>	<b>27.399</b>	<b>15.368</b>	<b>14.158</b>
Cost of sales	(12.763)	(12.028)	(6.636)	(5.901)
<b>Gross profit/(loss)</b>	<b>17.863</b>	<b>15.371</b>	<b>8.732</b>	<b>8.257</b>
Grants received for R&D	248	552	74	123
R&D contract income	1.119	1.109	521	534
R&D expenses	(10.405)	(13.961)	(5.381)	(6.979)
<b>Research and development</b>	<b>(9.038)</b>	<b>(12.300)</b>	<b>(4.786)</b>	<b>(6.322)</b>
Marketing & sales expenses	(7.310)	(7.919)	(3.682)	(3.867)
Administration expenses	(4.996)	(2.183)	(2.388)	(1.230)
<b>Operating expenses</b>	<b>(12.306)</b>	<b>(10.102)</b>	<b>(6.070)</b>	<b>(5.097)</b>
<b>Operating profit/(loss) before restructuring &amp; impairment losses</b>	<b>(3.481)</b>	<b>(7.031)</b>	<b>(2.124)</b>	<b>(3.162)</b>
<b>Restructuring &amp; impairment losses</b>	<b>(8.032)</b>	<b>-</b>	<b>3.332</b>	<b>-</b>
<b>Operating profit/(loss) (EBIT)</b>	<b>(11.513)</b>	<b>(7.031)</b>	<b>1.208</b>	<b>(3.162)</b>
Interest expenses	(1.786)	(1.483)	(935)	(1.014)
Interest income	375	554	154	423
Investment income and other	5.171	300	16	70
<b>Other income/(expenses)</b>	<b>3.760</b>	<b>(629)</b>	<b>(765)</b>	<b>(521)</b>
<b>Profit/(loss) before taxes</b>	<b>(7.753)</b>	<b>(7.660)</b>	<b>443</b>	<b>(3.683)</b>
Income taxes – (payable)/adjustment	(261)	(134)	(122)	(101)
<b>Net profit/(loss)</b>	<b>(8.014)</b>	<b>(7.794)</b>	<b>321</b>	<b>(3.784)</b>
<b>Operating profit/(loss) before depreciation and amortization (EBITDA)</b>	<b>(2.200)</b>	<b>(2.475)</b>	<b>800</b>	<b>(846)</b>
<b>EPS from continuing operations (basic/diluted)</b>	<b>(0,26)</b>	<b>(0,25)</b>	<b>0</b>	<b>(0,12)</b>
Shares used in computing per share amount (basic)	30.878.920	30.878.920	30.878.920	30.878.920
Shares used in computing per share amount (diluted)	30.880.072	30.878.920	30.880.072	30.878.920



**INNOGENETICS**<sup>®</sup>  
BIOTECHNOLOGY FOR HEALTHCARE

## Unaudited Consolidated Balance Sheet

	June 2008	December 2007
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents	15.665	23.478
Accounts receivable	18.127	19.060
Inventories	10.215	10.210
<u>Other accounts receivable</u>	<u>2.042</u>	<u>1.621</u>
<b>Total current assets</b>	<b>46.049</b>	<b>54.369</b>
<b>Non-current assets</b>		
Intangible assets	25.050	30.597
Property, plant and equipment	18.019	19.600
<u>Accounts receivable more than one year</u>	<u>357</u>	<u>359</u>
<b>Total non-current assets</b>	<b>43.426</b>	<b>50.556</b>
<b>TOTAL ASSETS</b>	<b>89.475</b>	<b>104.925</b>
<b>LIABILITIES &amp; SHAREHOLDERS' EQUITY</b>		
<b>Current liabilities</b>		
Current instalments of long-term obligations	8.777	9.932
Trade accounts payable	7.292	8.798
Other current liabilities	15.136	14.579
<u>Current tax liabilities</u>	<u>277</u>	<u>187</u>
<b>Total current liabilities</b>	<b>31.482</b>	<b>33.496</b>
<b>Non-current liabilities</b>		
Long-term obligations	36.054	41.039
Provisions	1.004	762
<u>Other non-current liabilities</u>	<u>1.233</u>	<u>1.677</u>
<b>Total non-current liabilities</b>	<b>38.291</b>	<b>43.478</b>
<b>Shareholders' equity</b>		
Share capital	19.398	19.398
Issuance premium	163.096	163.070
Reserves	(1.762)	(1.501)
<u>Retained earnings</u>	<u>(161.030)</u>	<u>(153.016)</u>
<b>Total shareholders' equity</b>	<b>19.702</b>	<b>27.951</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>89.475</b>	<b>104.925</b>



**INNOGENETICS**<sup>®</sup>  
BIOTECHNOLOGY FOR HEALTHCARE

## Unaudited Consolidated Statement of Shareholders' Equity

Movements during the six months of 2007

	Equity attributable to the equity holders of the Company					
	Number of shares issued	Share capital	Issuance premium	Retained earnings	Accumulated currency translation and fair value adjustments	TOTAL shareholders' equity
<b>Total as per December 31, 2006</b>	<b>30.878.920</b>	<b>19.398</b>	<b>157.419</b>	<b>(135.639)</b>	<b>(856)</b>	<b>40.322</b>
Currency translation adjustment					(131)	(131)
Net profit/(loss)				(7.794)		(7.794)
Recognition of share-based payment			110			110
Recognition of equity component of convertible bond			5.521			5.521
<b>Total as per June 31, 2007</b>	<b>30.878.920</b>	<b>19.398</b>	<b>163.050</b>	<b>(143.433)</b>	<b>(987)</b>	<b>38.028</b>

Movements during the six months of 2008

<b>Total as per December 31, 2007</b>	<b>30.878.920</b>	<b>19.398</b>	<b>163.070</b>	<b>(153.016)</b>	<b>(1.501)</b>	<b>27.951</b>
Currency translation adjustment					(261)	(261)
Net profit/(loss)				(8.014)		(8.014)
Recognition of share-based payment			26			26
Recognition of equity component of Convertible Bond						-
<b>Total as per June 30, 2008</b>	<b>30.878.920</b>	<b>19.398</b>	<b>163.096</b>	<b>(161.030)</b>	<b>(1.762)</b>	<b>19.702</b>



**INNOGENETICS**<sup>®</sup>  
BIOTECHNOLOGY FOR HEALTHCARE

## Unaudited Consolidated Statement of Cash Flows

	6 months ended		3 months ended	
	June 2008	June 2007	June 2008	June 2007
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>				
<b>Net Profit/(loss)</b>	<b>(8.014)</b>	<b>(7.794)</b>	<b>321</b>	<b>(3.784)</b>
Depreciation, amortization and impairment results	9.313	4.556	(408)	2.316
Increase/(decrease) in provisions	242	(2.556)	(3.586)	(627)
Share-based payment	26	111	7	27
Gain on disposal of fixed assets	(124)	(7)	(84)	30
Loss on disposal of fixed assets	44	126	1	96
Interest paid	1.786	1.510	935	1.031
Interest received	(351)	(511)	(141)	(380)
(Increase)/decrease in accounts receivable	511	1.055	5.514	677
(Increase)/decrease in inventories	(5)	(2.002)	723	(1.520)
(Increase)/decrease in current tax assets	-	-	-	22
Increase/(decrease) in accounts payable	(1.506)	602	(249)	1.068
Increase/(decrease) in accruals and other liabilities	(878)	(2.514)	447	(1.836)
Increase/(decrease) in current tax liabilities	90	(156)	51	(71)
Increase/(decrease) in non-current liabilities	(442)	(216)	(37)	(36)
<b>Total adjustments</b>	<b>8.706</b>	<b>(2)</b>	<b>3.173</b>	<b>797</b>
<b>Net cash used in operating activities</b>	<b>692</b>	<b>(7.796)</b>	<b>3.494</b>	<b>(2.987)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>				
Purchase of property, plant and equipment	(1.617)	(1.992)	(883)	(1.184)
Purchase of intangible assets	(489)	(1.245)	(187)	(146)
<b>Net cash used in investing activities</b>	<b>(2.106)</b>	<b>(3.237)</b>	<b>(1.070)</b>	<b>(1.330)</b>



**INNOGENETICS**<sup>®</sup>  
BIOTECHNOLOGY FOR HEALTHCARE

### Unaudited Consolidated Statement of Cash Flows (Continued)

	6 months ended		3 months ended	
	June 2008	June 2007	June 2008	June 2007
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>				
Payments on long-term obligations	(7.182)	(4.427)	(561)	(4.474)
Proceeds from long-term obligations	1.043	1.438	616	1.645
Payments on notes payable to bank	-	(1.435)	-	(522)
Proceeds from notes payable to bank	-	-	-	(199)
Currency translation adjustment	(260)	(131)	26	(87)
Proceeds from issuance of convertible bond	-	31.700	-	-
Transaction costs	-	(1.036)	-	-
<b>Net cash provided by/(used in) financing activities</b>	<b>(6.399)</b>	<b>26.109</b>	<b>81</b>	<b>(3.637)</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>(7.813)</b>	<b>15.076</b>	<b>2.505</b>	<b>(7.954)</b>
Cash and cash equivalents at beginning of year	23.478	22.349	13.160	45.379
<b>Cash and cash equivalents at end of period</b>	<b>15.665</b>	<b>37.425</b>	<b>15.665</b>	<b>37.425</b>



**INNOGENETICS**  
BIOTECHNOLOGY FOR HEALTHCARE

### Unaudited Segment Information

	Diagnostics 6 months ended		Therapeutics 6 months ended		Total 6 months ended	
	June 2008	June 2007	June 2008	June 2007	June 2008	June 2007
<b>Revenues</b>	<b>28.842</b>	<b>25.689</b>	<b>1.784</b>	<b>1.710</b>	<b>30.626</b>	<b>27.399</b>
<b>Gross profit</b>	<b>17.139</b>	<b>15.153</b>	<b>724</b>	<b>218</b>	<b>17.863</b>	<b>15.371</b>
Research & Development income	272	400	1.095	1.261	1.367	1.661
<u>Research &amp; Development expenses</u>	<u>(6.004)</u>	<u>(7.661)</u>	<u>(4.401)</u>	<u>(6.300)</u>	<u>(10.405)</u>	<u>(13.961)</u>
<b>Research &amp; Development</b>	<b>(5.732)</b>	<b>(7.261)</b>	<b>(3.306)</b>	<b>(5.039)</b>	<b>(9.038)</b>	<b>(12.300)</b>
<b>Operating expenses</b>	<b>(10.459)</b>	<b>(8.419)</b>	<b>(1.847)</b>	<b>(1.683)</b>	<b>(12.306)</b>	<b>(10.102)</b>
<b>Operating profit/(loss) before restructuring &amp; impairment losses</b>	<b>948</b>	<b>(527)</b>	<b>(4.429)</b>	<b>(6.504)</b>	<b>(3.481)</b>	<b>(7.031)</b>
<b>Restructuring &amp; impairment losses</b>	<b>(32)</b>	<b>-</b>	<b>(8.000)</b>	<b>-</b>	<b>(8.032)</b>	<b>-</b>
Operating profit/(loss) before depreciation and amortization (EBITDA)	4.160	2.872	(6.360)	(5.347)	(2.200)	(2.475)
<b>Operating profit/(loss) (EBIT)</b>	<b>916</b>	<b>(527)</b>	<b>(12.429)</b>	<b>(6.504)</b>	<b>(11.513)</b>	<b>(7.031)</b>